(Bloomberg) — Canada has licensed a startup to export psychedelics to Australia for patient use, the latest milestone in a contest to supply the potential growth of medical psychedelic drugs.
Full story here.
Regulator Filings
Consultants
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Stock Information
Trading Symbol: CSE: OPTI | OTC:OPTHF |
FRA: 8BN
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
WKN: A2QQEL
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
Product Disclaimer: Optimi Health products are still being investigated through a clinically validated development program for the purpose of applying for market authorization.
The safety and efficacy of our products has not been formally established.
© Copyright 2024 Optimi Health All rights reserved.
